| CAS NO: | 113558-89-7 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 113558-89-7 |
| 化学名 | N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide |
| Canonical SMILES | CC1=NC(CCN2CCC(C(C3=CC=C(NS(C)(=O)=O)C=C3)=O)CC2)=CC=C1 |
| 分子式 | C21H27N3O3S |
| 分子量 | 401.52 |
| 溶解度 | 25mg/mL in DMSO, 0.3mg/mL in DMF |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 7.7 nM for hERG E-4031 is an antiarrhythmic agent blocking the ATP-sensitive potassium channel. ATP-sensitive potassium channels are distributed in tissues widely including muscle, pancreatic beta cells and brain. Their activity is regulated by adenine nucleotides, being activated by falling ATP and rising ADP levels. Thus, ATP-sensitive potassium channels link cellular metabolism with membrane excitability. In vitro: It has been reported that E-4031 could induce EADs or TdP, and such induction correlated with a significant increase in variability of repolarization. In addition, E-4031 at 0.1 uM was able to significantly prolong cycle length, action potential duration, and depolarized maximum diastolic potential. E-4031could also reduce the upstroke velocity of the action potential as well as the diastolic depolarization rate [1]. In vivo: Animal study showed that E-4031 at 0.01 and 0.1 mg/kg could provide effective in-vitro plasma concentrations to significantly inhibit Ikr and thus delayed the repolarization beyond the initiation of diastole, leading to the inversion of electro-mechanical coupling, which provides an ideal proarrhythmic substrate [2]. Another sutdy found that E-4031 could prolong QT interval and ARI in all LV layers, though the magnitude of prolongation was greatest in Mid, particularly during bradycardia [3]. Clinical trial: Up to now, E-4031 is still in the preclinical development stage. References: |
m.cnreagent.com